Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab versus placebo for pain and inflammation in sickle cell disease
MOH_2017-03-14_000234Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Change in average daily pain from baseline between weeks 8 and 12. Started Mar 2017; status: completed.
02
Drugs
canakinumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on MOH_2017-03-14_000234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000234.